CordenPharma CordenPharma stands as a prominent leader in the pharmaceutical industry, specializing in the effective production of peptide Active Pharmaceutical Ingredients (APIs). With a significant and ongoing commitment to expanding its capabilities, CordenPharma is solidifying its position as a key player in the global peptide market. The company's strategic investments underscore its dedication to meeting the increasing demand for high-quality peptide-based therapeutics and driving innovation in peptide development and manufacturing.
CordenPharma has announced substantial investments aimed at significantly boosting its peptide manufacturing capacity. Notably, the company is investing approximately €900 million (over $984 million USD) over the next three years.Get in touch with our team of expertsto explore bespoke end-to-end CDMO support of your complete drug lifecycle at any scale. This investment is earmarked for expanding its peptide platform across its global facilities, including significant developments in Colorado and Europe. A key component of this expansion is the establishment of a new, state-of-the-art peptide manufacturing facility in Switzerland, located at Getec Park in Muttenz, near Basel. This facility, slated for completion, represents a major step forward in enhancing CordenPharma's ability to produce complex peptides at various scalesThe Peptides Platform offersmall to large-scale Peptide manufacturingfor GLP-1s, short and long peptides, including oral peptide delivery..
Further underscoring its ambitious growth strategy, CordenPharma unveiled plans for a total strategic investment exceeding €1 billionpeptides - Corden Pharma GmbH - Pharmaceutical Tech. This extensive capital expenditure is designed to enhance its peptide development and manufacturing capabilities, positioning the company to meet future market demands and broaden its service offerings2024年7月17日—The Swiss drug services firm CordenPharmaplans a giant investment in its peptide manufacturing businessover the next 3 years.. These investments reflect CordenPharma's proactive approach to scaling operations and maintaining its competitive edge in the rapidly evolving pharmaceutical landscape.
As one of the leading manufacturers of peptide Active Pharmaceutical Ingredients (APIs), CordenPharma offers a comprehensive suite of services that span the entire drug lifecycle.CordenPharma | Corden Pharma - A Full-Service CDMO The company provides end-to-end CDMO (Contract Development and Manufacturing Organization) support, from early-stage clinical development through to successful commercialization. CordenPharma's expertise covers a wide range of peptide types, including GLP-1 peptides, short and long peptides, and caters to various delivery methods, such as injectable and oral peptide formulations.2020年7月7日—The expansion has been planned to enableCordenPharmato manufacture a complex longpeptidewith a 400 kg output per single batch.
The company's technological advancements include innovative methods like TAPS (TAG-Assisted Peptide Synthesis), a green and cost-effective approach to peptide manufacturing.2025年3月12日—The expansion plans ofCordenPharmaare designed to increase sales in itspeptidebusiness to more than 1 billion euros by 2028. This commitment to advanced synthesis techniques allows CordenPharma to efficiently produce peptides on a small to large-scale basis, meeting the diverse needs of its clients.2024年7月23日—The expansions aim to helpCordenPharmareach 1 billion euros in sales for both its injectable and oralpeptidesby 2028. The integration of these technologies ensures both high yield and sustainability in their manufacturing processes.
CordenPharma's strategic expansion is not limited to a single region. The company is actively developing and expanding small, medium, and large manufacturing facilities across both Europe and the United States. This global footprint allows CordenPharma to serve a diverse client base and ensure supply chain resilience.CordenPharma to build €500M Swiss peptide plant ... The recent commissioning of new GMP capacities at its Frankfurt site for the manufacture of early clinical phase peptide APIs further demonstrates its commitment to supporting clients from the earliest stages of drug development.
The company's vision extends to achieving significant sales growth in its peptide business, with targets set to reach over €1 billion by 2028 for both injectable and oral peptide products. This ambitious goal is supported by ongoing investments in R&D, state-of-the-art infrastructure, and a highly skilled workforce dedicated to delivering excellence in peptide API manufacturing.
CordenPharma positions itself as a trusted partner for companies seeking specialized peptide manufacturing services.CordenPharmaenters the synthetic oligonucleotide manufacturing arena with capex investment in two phases and fully-integrated APIs to Drug Product offerings. Their "Peptides Platform" is designed to provide bespoke, end-to-end CDMO support, leveraging extensive experience and a robust global network of facilities. By collaborating with CordenPharma, clients can benefit from a seamless transition from drug substance discovery to drug product manufacturing, ensuring regulatory compliance and quality at every step. The company's dedication to innovation, capacity expansion, and client-focused solutions solidifies its role as a critical enabler of novel peptide therapeutics reaching patients worldwide.
Join the newsletter to receive news, updates, new products and freebies in your inbox.